Chemotherapy

Risk factors for damaged liver function after chemotherapy in hepatitis B virus carriers with non-Hodgkin lymphoma

X. Li, Fan, X. W., Liu, W., Guo, L., Li, Y., Hu, X., Liang, X., Ma, X. P., and Yang, S. E., “Risk factors for damaged liver function after chemotherapy in hepatitis B virus carriers with non-Hodgkin lymphoma”, vol. 14, pp. 2647-2653, 2015.

The goal of this study was to investigate damaged liver function after chemotherapy in hepatitis B virus (HBV) carriers with non-Hodgkin lymphoma (NHL) and to evaluate risk factors associated with a high risk of damaged liver function. Clinical histories of 134 HBV carriers with NHL who were treated with chemotherapy were obtained and analyzed for the occurrence of damaged liver function and other related high-risk factors.

Isolation and characterization of cancer stem cells from medulloblastoma

J. Liu, Chi, N., Zhang, J. Y., Zhu, W., Bian, Y. S., and Chen, H. G., “Isolation and characterization of cancer stem cells from medulloblastoma”, vol. 14, pp. 3355-3361, 2015.

Brain cancer stem cells are a subset of tumor cells present in several types of brain tumor that evade treatment regimens and are responsible for tumor recurrence. Recent reports on several tumors have suggested that Hoechst 33342 dye exclusion is a powerful technique for isolating cancer stem cell-like side population (SP) cells. In the present study, we attempted to isolate the SP cells from medulloblastoma, a malignant brain tumor in children. The tumor samples obtained were subjected to fluorescence-activated cell sorting analysis for SP cell isolation.

Effect of polymorphisms of vascular endothelial growth factor on prognosis in osteosarcoma patients

X. D. Li, Yu, D. D., Lu, J. R., Wu, C., and Jin, W. X., “Effect of polymorphisms of vascular endothelial growth factor on prognosis in osteosarcoma patients”, vol. 14, pp. 4354-4360, 2015.

We investigated the association between vascular endothelial growth factor (VEGF) gene +1612G/A, -634C/G, and +936G/C and the clinical outcome of osteosarcoma. Genomic DNA was isolated from blood samples, and 3 VEGF gene polymorphisms (+1612G/A, -634C/G, and +936G/C) were analyzed using polymerase chain reaction-restriction fragment length polymorphism. Of the 194 patients, 82 patients (42.27%) showed a good response to chemotherapy, while 73 (37.63%) died during the follow-up period.

Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy

L. Zhang, Ma, W., Li, Y., Wu, J., and Shi, G. Y., “Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy”, vol. 13, pp. 228-236, 2014.

Individual differences in chemosensitivity and clinical outcome of non-small-cell lung carcinoma (NSCLC) patients can be influenced by host-inherited factors. We investigated the impact of XRCC1 Arg194Trp, XRCC1 Arg280His, XRCC1 Arg399Gln, XPD Arg156Arg, XPD Asp312Asn, XPD Asp711Asp, and XPD Lys751Gln gene polymorphisms on treatment efficacy in 375 NSCLC patients on platinum-based chemotherapy. We also examined progression-free survival and overall survival. The gene polymorphisms were analyzed by duplex PCR.

Pleural resection and pleural infusion chemotherapy for therapy of malignant pleural mesothelioma

J. Zhang, Zhang, Q., Zhao, W., Duan, J., and Huang, T., “Pleural resection and pleural infusion chemotherapy for therapy of malignant pleural mesothelioma”, vol. 13, pp. 483-489, 2014.

The aim of this study was to evaluate effective treatment methods of malignant pleural mesothelioma (MPM). Twenty-three patients with MPM were cured by pleural infusion chemotherapy after surgery. Median survival time and the 1-, 2-, and 3-year survival rates were analyzed on the basis of follow-up. Median survival time of all patients was 15 months (range: 3 to 89 months); the 1-, 2-, and 3-year survival rates were 69.6, 43.5, and 13.0%, respectively.

Pharmacogenetic role of XRCC1 polymorphisms on the clinical outcome of gastric cancer patients with platinum-based chemotherapy: a systematic review and meta-analysis

J. Xu, Ma, J., Zong, H. T., Wang, S. Y., and Zhou, J. W., “Pharmacogenetic role of XRCC1 polymorphisms on the clinical outcome of gastric cancer patients with platinum-based chemotherapy: a systematic review and meta-analysis”, vol. 13, pp. 1438-1446, 2014.

It is still controversial whether X-ray repair cross-complementing group (XRCC1) gene polymorphisms (Arg194Trp and Arg399Gln) are associated with the clinical outcome of platinum-based chemotherapy in gastric cancer patients based on published studies. Meta-analysis was performed to provide a systematic review of the findings. Eligible articles from the PubMed, SinoMed, and CNKI databases before September 1, 2012, were selected.

Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis

L. Li, Wan, C., and Wen, F. Q., “Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis”, vol. 13, pp. 3772-3786, 2014.

X-ray repair cross complementing group 1(XRCC1) polymorphisms have been implicated in interindividual variability of efficacy of platinum chemotherapy for treating non-small cell lung cancer (NSCLC); however, results of different studies have been inconsistent. We conducted a meta-analysis to investigate the association between polymorphisms in the XRCC1 gene and response rate of platinum chemotherapy in advanced NSCLC patients.

Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer

H. Gao, Ge, R. C., Liu, H. Y., Wang, Y., and Yan, S., “Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer”, vol. 13, pp. 8997-9004, 2014.

We conducted a cohort study to investigate the role of 3 single-nucleotide polymorphisms of the excision repair cross-complementation group 1 (ERCC1) gene on the response to chemotherapy and clinical outcomes of non-small cell lung cancer (NSCLC). A total of 163 patients with newly diagnosed and histopathologically confirmed primary NSCLC were examined in our study and were followed up until December 2012. ERCC1 rs11615, rs3212986, and rs2298881 were selected and genotyped.

Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer

F. F. O. Rodrigues, Santos, R. E., Melo, M. B., Silva, M. A. L. G., Oliveira, A. L., Rozenowicz, R. L., Ulson, L. B., and Aoki, T., “Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer”, vol. 7, pp. 177-183, 2008.

Primary chemotherapy is a useful strategy for the treatment of locally advanced breast cancer and therefore allows in vivo evaluation of the action of cytotoxic drugs and the possibility of accomplishing conservative breast surgeries, as well as the early treatment of metastasis. Mechanisms of resistance to the drugs include the action of protein associated with the efflux of drugs from the intracellular environment hindering their activity; one of the most studied proteins is P-glycoprotein codified by the MDR-1 gene.

Subscribe to Chemotherapy